ABOUT The nRollMed Team

Experience that matters

Gil Pal

Chief Executive Officer

Gil brings 20 years of experience in software development and marketing to his leadership at nRollmed.

Gil was a serial entrepreneur with several startups in the employment recruitment industry (Donanza, See.V) when he launched the company in 2014. He was driven by a strong personal desire to help advance the medical field.  

Gil started his professional career in the prestigious cyber unit of the Israel Defense Force (IDF) and holds a B.A. in Computer Science and psychology from Bar-Ilan University.

Lily Marcus

Clinical Project Manager

Lily joined nRollmed in 2018. She is the lead project manager in charge of helping clinical sites meet their recruitment goals. She holds a B.Sc. in neuroscience and psychology from Brandeis University and an M.Sc. in neurobiology from The Hebrew University. She brings to nRollmed her scientific background, a passion for new healthcare technologies, and an eye for detail.

Diana headshot

Diana Gavrilov Negev

Clinical Operations Manager

Diana is an experienced Clinical Operations Manager and regulatory professional with a demonstrated history of working in the pharmaceuticals and medical device industries. She is a research professional with an MBA focused on Health Management and pharmaceutical systems.

Book a discovery call
Isaac headshot

Isaac Toenies

Screening Agent

Isaac brings 12 years of experience in healthcare and allied fields, including 2 years in patient recruitment, screening, and engagement. At nRollmed, Isaac deploys knowledge in biology, pharmacology, and medicine–along with people skills honed in customer service and frontline patient care.

Avi Yaron

Strategic Advisor

Avi is a visionary entrepreneur, executive chairman and strategic adviser, with extensive knowledge in the medical and neurotech arenas. Avi is passionate about disrupting medicine, enhancing life quality, and utilizing advanced technologies for patient needs.

Carey headshot

Carey Fried

Chief Marketing Officer

Carey recently joined the nRollmed team and brings 20 years of deep experience in B2B marketing. As CMO, she is responsible for building the company’s multi-channel marketing strategy, aligning sales and marketing to drive revenue.

Book a discovery call
Book a discovery call
About nRollMed

Extensive experience & proficiency

Extensive experience & proficiency in the clinical trials industry, software development, and marketing. Read what our customers have to say!

A proven track record

A proven track record of enhanced clinical trial performance—up to 80% of total randomized patients,
up to 50% faster enrollment. Explore our case studies for time-saving benefits

Worldwide services

Worldwide services for every indication at any location. Proven experience in hundreds of sites across the US, Europe, and the Middle East.


Customized services & strategies that fit your study’s needs, timeline, and budget.

Info security & compliance

Info security & compliance ISO 27001 / 27799 certified. GDPR & HIPAA compliant.

Numerous therapeutic fields

Numerous therapeutic fields: gynecology, psychiatry, gastroenterology, ophthalmology, oncology, and more.

Book a discovery call
Gil’s efforts led Google to change policy

Google restricts the promotion of healthcare-related content such as OTC medicine, medical services & procedures, medical claims, and clinical trial recruitment. That’s Google’s official policy. 

But, Gil realized that those restrictions depend on the content and the countries where ads appear.

Back in 2015, Google started to enforce its restrictions in Israel regarding patient recruitment to clinical trials.

At that time, nRollmed had several recruitment projects in Israel and the Google policy could significantly hurt the industry and nRollmed’s mission to make clinical trials accessible to whomever is looking for innovative treatments; the effects on clients would have been significant as well.

nRollmed worked vigorously to add Israel to the limited list of countries where Google allowed the promotion of clinical trials.

Ultimately, in September 2015, Google reversed its decision to the satisfaction of our clients and to the benefit of the local industry.

See the Google announcement.